Patents by Inventor Daren R. Ure

Daren R. Ure has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • USE OF CYCLOSPORINE ANALOGUES AS ANTITHROMBOTIC AGENTS
    Publication number: 20220168385
    Abstract: Disclosed herein include methods, compositions, and kits suitable for use in preventing/treating a thromboembolic disorder, preventing/reducing formation of thrombi, and reducing/inhibiting procoagulant platelet formation. The methods comprise administering to a subject in need thereof a composition comprising a cyclosporine analogue (for example, CRV431). The compositions and kits comprise a cyclosporine analogue.
    Type: Application
    Filed: November 26, 2021
    Publication date: June 2, 2022
    Inventors: Daren R. Ure, Robert T. Foster, Daniel J. Trepanier, Patrick R. Mayo
  • USE OF CYCLOSPORINE ANALOGUES FOR TREATING CANCER
    Publication number: 20210269479
    Abstract: Disclosed herein include methods, compositions, and kits suitable for use in preventing and treating proliferative diseases such as cancer. The methods comprise administering to a subject in need thereof a composition comprising a cyclosporine analogue (e.g., CRV431), or a pharmaceutically acceptable salt, solvate, stereoisomer thereof. The compositions and kits comprise a cyclosporine analogue (e.g., CRV431), or a pharmaceutically acceptable salt, solvate, stereoisomer thereof.
    Type: Application
    Filed: February 24, 2021
    Publication date: September 2, 2021
    Inventors: Daren R. Ure, Daniel J. Trepanier, Patrick R. Mayo, Robert T. Foster
  • USE OF CYCLOSPORINE ANALOGUES FOR TREATING FIBROSIS
    Publication number: 20210260153
    Abstract: Disclosed herein include methods, compositions, and kits suitable for use in preventing, treating or reverse fibrosis. The methods comprise administering to a subject in need thereof a composition comprising a cyclosporine analogue (for example, CRV431), or a pharmaceutically acceptable salt, solvate, stereoisomer thereof. The compositions and kits comprise a cyclosporine analogue (for example, CRV431), or a pharmaceutically acceptable salt, solvate, stereoisomer thereof.
    Type: Application
    Filed: February 19, 2021
    Publication date: August 26, 2021
    Inventors: Daren R. Ure, Daniel J. Trepanier, Patrick R. Mayo, Robert T. Foster
  • Cyclosporine analogue molecules modified at amino acid 1 and 3
    Patent number: 9714271
    Abstract: Analogs of cyclosporin-A are disclosed comprising modifications of the substituents as the positions of amino acids 1 and 3, according to the following Formula. The disclosed compounds include compounds having affinity for cyclophilin, including cyclophilin-A, and reduced immunosuppressivity in comparison with cyclosporin-A and analogs thereof modified solely at position 1.
    Type: Grant
    Filed: October 30, 2015
    Date of Patent: July 25, 2017
    Assignee: ContraVir Pharmaceuticals, Inc.
    Inventors: Alexander Hegmans, Bruce W. Fenske, Dan J. Trepanier, Mark D. Abel, Daren R. Ure, Shin Sugiyama
  • Cyclosporine Analogue Molecules Modified At Amino Acid 1 and 3
    Publication number: 20160207961
    Abstract: Analogues of cyclosporin-A are disclosed comprising modifications of the substituents as the positions of amino acids 1 and 3, according to the following Formula. The disclosed compounds include compounds having affinity for cyclophilin, including cyclophilin-A, and reduced immunosuppressivity in comparison with cyclosporin-A and analogs thereof modified solely at position 1.
    Type: Application
    Filed: October 30, 2015
    Publication date: July 21, 2016
    Inventors: Alexander Hegmans, Bruce W. Fenske, Dan J. Trepanier, Mark D. Abel, Daren R. Ure, Shin Sugiyama
  • Cyclosporine analogue molecules modified at amino acid 1 and 3
    Patent number: 9200038
    Abstract: Analogs of cyclosporin-A are disclosed comprising modifications of the substituents as the positions of amino acids 1 and 3, according to the following Formula. The disclosed compounds include compounds having affinity for cyclophilin, including cyclophilin-A, and reduced immunosuppressivity in comparison with cyclosporin-A and analogs thereof modified solely at position 1.
    Type: Grant
    Filed: December 14, 2011
    Date of Patent: December 1, 2015
    Assignee: Ciclofilin Pharmaceuticals Corp.
    Inventors: Alexander Hegmans, Bruce W. Fenske, Dan J. Trepanier, Mark D. Abel, Daren R. Ure, Shin Sugiyama
  • CYCLOSPORINE ANALOGUE MOLECULES MODIFIED AT AMINO ACID 1 AND 3
    Publication number: 20140142033
    Abstract: Analogues of cyclosporin-A are disclosed comprising modifications of the substituents as the positions of amino acids 1 and 3, according to the following Formula. The disclosed compounds include compounds having affinity for cyclophilin, including cyclophilin-A, and reduced immunosuppressivity in comparison with cyclosporin-A and analogs thereof modified solely at position 1.
    Type: Application
    Filed: December 14, 2011
    Publication date: May 22, 2014
    Applicant: Isotechnika Pharma Inc.
    Inventors: Alexander Hegmans, Bruce W. Fenske, Dan J. Trepanier, Mark D. Abel, Daren R. Ure, Shin Sugiyama
  • DENDRITIC CELL POTENTIATION
    Publication number: 20110065178
    Abstract: A molecule capable of potentiating immune responses is described, as well as methods for using the molecule to enhance immune responses and enhance dendritic cell function. Also described are compositions containing the molecule and methods for using the compositions to treat or immunize individuals.
    Type: Application
    Filed: June 30, 2010
    Publication date: March 17, 2011
    Applicant: MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH
    Inventors: Larry R. Pease, Moses Rodriguez, Daren R. Ure, Bogoljub Ciric, Virginia Van Keulen